Biphenylsulfonamide Endothelin Receptor Antagonists. 2. Discovery of 4‘-Oxazolyl Biphenylsulfonamides as a New Class of Potent, Highly Selective ETA Antagonists
Citations Over TimeTop 19% of 2000 papers
Abstract
The synthesis and structure-activity relationship (SAR) studies of a series of 4'-oxazolyl-N-(3,4-dimethyl-5-isoxazolyl)[1, 1'-biphenyl]-2-sulfonamide derivatives as endothelin-A (ET(A)) receptor antagonists are described. The data reveal a remarkable improvement in potency and metabolic stability when the 4'-position of the biphenylsulfonamide is substituted with an oxazole ring. Additional 2'-substitution of an acylaminomethyl group further increased the binding activity and provided one of the first subnanomolar ET(A)-selective antagonists in the biphenylsulfonamide series (17, ET(A) K(i) = 0.2 nM). Among the compounds described, 3 (N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1, 1'-biphenyl]-2-sulfonamide; BMS-193884) had the optimum pharmacological profile and was therefore selected as a clinical candidate for studies in congestive heart failure.
Related Papers
- → Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2(2020)34 cited
- → Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors(2007)33 cited
- → Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists(2013)10 cited
- → Design, synthesis and structure–activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent γ-secretase inhibitors(2011)9 cited
- → Structure–activity relationships of triazolopyridine oxazole p38 inhibitors: Identification of candidates for clinical development(2006)28 cited